James Bhatt

James Bhatt is a clinical investigator in NASH therapeutics with expertise in how new NASH treatments including resmetirom (Rezdiffra) may impact long-term HCC risk. His research has analyzed the MAESTRO-NASH trial data to characterize which patients achieve histological NASH resolution and fibrosis improvement with resmetirom. He is investigating whether fibrosis reversal with resmetirom and other agents translates into reduced HCC risk in NASH patients. His work also addresses systemic therapy outcomes in patients with NASH-HCC compared to viral or alcohol-related HCC.